NCT07176000 Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial
| NCT ID | NCT07176000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Lung Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 237 participants |
| Start Date | 2026-09-15 |
| Primary Completion | 2029-03-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 237 participants in total. It began in 2026-09-15 with a primary completion date of 2029-03-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether tailored patient navigation (PN) works to improve the uptake of lung cancer screening (LCS) in tribal communities in western Washington state. Lung cancer is the leading cause of cancer death in the United States among American Indian (AI) and Alaska Native (AN) people, and the incidence of lung cancer is higher in this population in the Northern and Southern Plains, Alaska, and Pacific Coast regions. In Washington state, AI/AN people also have twice the rate of commercial cigarette smoking than the overall population. LCS with annual low-dose chest computed tomography (CT) can reduce lung cancer death and is recommended in people 50-80 years of age with current or recent (within 15 years) tobacco use and a 20 pack-year or greater smoking history. Despite this, AI and AN people are less likely to receive LCS which may be due to barriers they face making it difficult to receive LCS. PN services are designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The PN services in this trial have been tailored for the tribal communities in western Washington state. The services are designed to help participants overcome the unique barriers that their tribal communities face and improve the uptake of LCS.
Eligibility Criteria
Inclusion Criteria: * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Between ages 50-77 * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Self-reported 20-pack year smoking history * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Ongoing commercial tobacco use within the past 15 years * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Seen by a PCP at a participating clinic (South Puget Intertribal Planning Agency \[SPIPA\] or Muckleshoot) within the past three years * Potential participants who want to establish care at an eligible clinic will be connected to a PCP * AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age * AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member * AIM 2 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial * AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age * AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member * AIM 3 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial Exclusion Criteria: * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Has had a documented chest CT within the past one year * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Personal history of lung cancer * AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Personal history of any cancer within 5 years except for basal cell or squamous cell skin carcinoma
Contact & Investigator
Matty Triplette, MD, MPH
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT07176000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07176000 currently recruiting?
Yes, NCT07176000 is actively recruiting participants. Contact the research team at mtriplet@fredhutch.org for enrollment information.
Where is the NCT07176000 trial being conducted?
This trial is being conducted at Auburn, United States, Shelton, United States.
Who is sponsoring the NCT07176000 clinical trial?
NCT07176000 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Matty Triplette, MD, MPH at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 237 participants.